The broad overall objective of this competing renewal grant application is to develop novel prodrug strategies to improve ocular antiviral drug therapy, in the treatment of human cytomegalovirus (HCMV) retinitis. In the previous grant period, microdialysis technique has been utilized to study ocular pharmacokinetics in anesthetized and conscious animal models. Retinal drug delivery may be enhanced by exploiting the membrane transporters on the neural retina, RPE and/or endothelial cells of the retinal blood vessels. We propose to synthesize a series of dipeptide, amino acid and folate mono- and di- ester prodrugs of ganciclovir (GCV) to target peptide, amino acid and folate transporters/receptors respectively. The proposed prodrugs would not only improve the ocular bioavailability of GCV, but also may exhibit diminished cytotoxicity, require lower doses, and a decreased frequency of administration. By simultaneous targeting of multiple transporters having no overlapping substrate specificity, we can achieve higher intracellular concentrations of GCV due to enhanced uptake of the prodrugs followed by enzymatic conversion in the retinal cells.
The specific aims of this renewal application are: 1. To synthesize mono- and di-ester derivatives of GCV targeting peptide transporters - Val-Val-GCV, Val-Gly-GCV, Gly-Val- GCV, Gly-Tyr-GCV and Val-Tyr-GCV; amino acid transporters - gamma,-Glu-GCV, Phe-GCV, Tyr-GCV and Trp-GCV; and folate transport systems - folate ester of GCV. 2. To determine antiviral efficacy and cytotoxicity of the proposed compounds against in vitro viral screens of HCMV, HSV-1, HSV-2, VZV, and EBV and to conduct in vivo efficacy studies against HCMV retinitis in SCID mouse model, by NIAID supported research at the University of Alabama, Birmingham (P.I. Dr. Earl Kern). 3. To conduct uptake studies of dipeptide, amino acid (targeted to glutamate, LNAA transporters) and folate (targeted to folic acid receptors/transporters) mono- and di-ester prodrugs of GCV, a) in vitro, using ARPE-19 cell line, and b) ex vivo/in vivo, using rabbit retina.
Our aim i s also to study the retinal concentrations of GCV following simultaneous administration of a prodrug combination targeted towards peptide, amino acid and folate transporters. 4. To evaluate in vivo ocular bioavailability of GCV in the vitreous and anterior chambers utilizing dual probe ocular microdialysis technique following IV and intravitreal administrations. The ocular bioavailability of GCV upon administration of a prodrug combination targeted towards peptide, amino acid and folate transporters will be determined. 5. i) to develop a novel injectable, biodegradable, thermosensitive in situ gel forming system, containing drug and drug loaded microspheres and (ii) to evaluate in vivo ocular bioavailability of GCV with microdialysis technique following episcleral deposition of the gel formulation in a conscious animal model.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY010659-11
Application #
7090608
Study Section
AIDS and Related Research 8 (AARR)
Program Officer
Shen, Grace L
Project Start
1996-04-01
Project End
2007-07-31
Budget Start
2006-08-01
Budget End
2007-07-31
Support Year
11
Fiscal Year
2006
Total Cost
$212,389
Indirect Cost
Name
University of Missouri Kansas City
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
010989619
City
Kansas City
State
MO
Country
United States
Zip Code
64110
Mandal, Abhirup; Pal, Dhananjay; Agrahari, Vibhuti et al. (2018) Ocular delivery of proteins and peptides: Challenges and novel formulation approaches. Adv Drug Deliv Rev 126:67-95
Agrahari, Vibhuti; Agrahari, Vivek; Mandal, Abhirup et al. (2017) How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches. Expert Opin Drug Deliv 14:1145-1162
Joseph, Mary; Trinh, Hoang M; Cholkar, Kishore et al. (2017) Recent perspectives on the delivery of biologics to back of the eye. Expert Opin Drug Deliv 14:631-645
Mandal, Abhirup; Bisht, Rohit; Rupenthal, Ilva D et al. (2017) Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies. J Control Release 248:96-116
Mandal, Abhirup; Cholkar, Kishore; Khurana, Varun et al. (2017) Topical Formulation of Self-Assembled Antiviral Prodrug Nanomicelles for Targeted Retinal Delivery. Mol Pharm 14:2056-2069
Agrahari, Vibhuti; Agrahari, Vivek; Hung, Wei-Ting et al. (2016) Composite Nanoformulation Therapeutics for Long-Term Ocular Delivery of Macromolecules. Mol Pharm 13:2912-22
Patel, Sulabh P; Vaishya, Ravi; Patel, Ashaben et al. (2016) Optimization of novel pentablock copolymer based composite formulation for sustained delivery of peptide/protein in the treatment of ocular diseases. J Microencapsul 33:103-13
Agrahari, Vibhuti; Mandal, Abhirup; Agrahari, Vivek et al. (2016) A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res 6:735-754
Agrahari, Vibhuti; Agrahari, Vivek; Mitra, Ashim K (2016) Nanocarrier fabrication and macromolecule drug delivery: challenges and opportunities. Ther Deliv 7:257-78
Cholkar, Kishore; Gilger, Brian C; Mitra, Ashim K (2016) Topical delivery of aqueous micellar resolvin E1 analog (RX-10045). Int J Pharm 498:326-34

Showing the most recent 10 out of 150 publications